Results: AVO

Search articles by EPIC code
EPIC AVO
views

Advanced Oncotherapy is a slam dunk short

I should declare that I am a shareholder in this company. I bought 1 share a few years ago so that I could attend its AGM to quiz the management on the catalogue of lies they had told to investors.  Then covid struck. On a properly regulated market Advanced Oncotherapy (AVO) would have been given the order of the boot years ago, but this is AIM.

EPIC AVO
views

Advanced Oncotherapy – Has Odey Doubled Down In Face Of Embarrassment Of Insolvency?

AIM-listed Advanced Oncotherapy (AVO) has announced that Odey Asset Management is coughing up another £4.5 million as part of a £6 million fundraise to add to its investment in March of £2 million, again at 25p a pop – the par price. So is this an act of faith by Odey, or a case of if you owe the bank a million quid then it is the bank which has a problem?

EPIC AVO
views

Advanced Oncotherapy – Yet Another Placing To Kick The Fat Lady Down The Road By Only A Few Inches

AIM-listed Advanced Oncotherapy (AVO) is certainly keeping its Brokers – SI Capital and Allenby – busy. Only in April the company raised £1.7 million, although the funds weren’t in the bank when the announcement went out. In March the company rattled the tin for £2 million – plus an additional loan of another £1.5 million. Now it has rattled the tin once again – to raise just £800,000 (before expenses) as the company strains to keep its head above water.

EPIC AVO
views

Advanced Oncotherapy – Flip-flop Delay To Fundraise!

On 12th April 2022 AIM-listed Advanced Oncotherapy (AVO) announced an equity fundraise of £1.735 million at 25p a pop – a premium to market, but only at par price. We were told that the fundraise has been conducted through a direct subscription with the Company (the "Subscription") for a total of 6,940,000 new ordinary shares. So the money was in the bank, right? Wrong….

EPIC AVO
views

Advanced Oncotherapy – When’s The Placing As Cash-Crisis Mounts Amid Shares Falling Below Par

I noted at the beginning of this month that AIM-listed Advanced Oncotherapy (AVO) needs to get a fundraise away pronto, but that its shares were threatening to drop below the nominal price of 25p, below which it cannot issue new shares by law. On Friday the shares closed at 24p (mid) and I would suggest that Advanced – or, rather, its shareholders – have a big problem.

Page 1 of 25 (250 articles)
Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Complete Coverage

Recent Comments